Sanofi Buys Principia for USD 3.7 Billion as Part of Specialty Pivot
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
Address: 823 Jays Drive
Lansdale, PA 19446,United States of America
Tel:
Web: http://www.jdptherapeutics.com/default.aspx
JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life-threatening diseases with significant unmet medical needs, primarily for use in acute care in a hospital setting.
Small Molecule Therapeutics
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s specialty portfolio in the US market, the challenges of…
Executives from ALK, Sanofi Genzyme and Novartis discuss how they are navigating pricing and reimbursement issues in the USA, home to the world’s largest – but perhaps most complex –…
With COVID-19 having wreaked havoc on global operations, the pharma industry is understandably focused on leveraging its collective resources and knowhow in discovering and delivering prophylactics and therapeutics against the…
Ameet Mallik, Executive VP and Head of Oncology for the US at Novartis Oncology highlights the company’s culture of ‘curious, inspired, and unbossed,’ how Novartis differentiates itself in a highly…
Alper Ureten, Amgen VP and General Manager, sits down with PharmaBoardroom to set out his ambitions and objectives for its Biosimilars Business Unit. Ureten also reveals the strategy behind their…
William H Lewis, chairman and CEO of serious and rare disease specialist Insmed, talks through the impact of recent product approvals in the US, preparations underway for international launches, the…
Ulrich Neumann examines the debate around drug pricing in the US and why it is not going away any time soon. Come senators, congressmen Please heed the call Don’t…
John G. Singer examines why technological solutions are not a quick fix to overcoming the COVID-19 crisis and how a systems shift is crucial to securing better health outcomes in…
Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to…
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new products in the midst of a global pandemic…
Dan Leonard, Kimberly Westrich, and Brian Sils of the National Pharmaceutical Council examine how a new HHS ruling on how US patients pay for medicines could hurt them financially, exacerbating…
See our Cookie Privacy Policy Here
